Bio & Pharma
Korea's ST Pharm completes new R&D hub for gene therapy
The new R&D center will house synthetic and oligo research institutes, allowing better collaboration among its scientists
By Mar 03, 2023 (Gmt+09:00)
1
Min read
Most Read
LG Chem to sell water filter business to Glenwood PE for $692 million


Kyobo Life poised to buy Japan’s SBI Group-owned savings bank


KT&G eyes overseas M&A after rejecting activist fund's offer


StockX in merger talks with Naver’s online reseller Kream


Mirae Asset to be named Korea Post’s core real estate fund operator



ST Pharm Co., a South Korean drug raw material-producing subsidiary of Dong-A Socio Holdings, said on Friday that it has finished building an R&D Innovation Center in Ansan City, Gyeonggi Province.
The 12-story center, which spans 5,166 square meters and cost 18 billion won ($14 million) to construct, opened on Feb. 3 after starting work in January last year.
The company said the center will house synthetic and oligo research institutes, which were previously located in Siwha and Banwol, both in Gyeonggi Province. This will allow better collaboration and research among its scientists.
The center will also host a quality control department to offer faster contract development and manufacturing (CDMO) services for oligonucleotide therapeutics.
A company official said the center will help the company enlist top researchers and boost its CDMO services, its main business area. He also said the center will serve as a key base for developing new drugs and creating new platforms for gene therapy.
Write to Ji-Hyun Lee at bluesky@hankyung.com
More to Read
-
Bio & PharmaST Pharm exports $14.6 mn worth of drug ingredients to Europe
Jan 20, 2023 (Gmt+09:00)
1 Min read -
-
Bio & PharmaK-bio firms embrace gene therapy CDMO as Samsung looks the other way
Aug 05, 2022 (Gmt+09:00)
3 Min read
Comment 0
LOG IN